Liver recipients. The eight patients were 21~ to 16 years of age (Table I) . Four had biliary atresia; of these, three had had one or more previous attempts at porticoenterostomy (Kasai procedure), and the earlier operations made transplantation difficult. Other diagnoses are shown in Table I .
Abbreviations used
CyA: cyclosporin A DR:
D-relatcd Donor selection was random in respect to the HLA A, B and D loci. Matches of the four antigens of the A and B loci averaged 1.0 ± 0.7 (SD), range 0 to 2. Two DR matches were present in one case, one match existed in two cases, and no matches were present in the other six donor-recipient combinations.
In two instances, grafts were placed into recipients who had pre-existing anti-donor antibodies. In one (No. 8 transplantation. One to three HLA antigens were matched (Table II) . No DR antigen matches were found between any of the donors and recipients. The operations. Liver transplantation. Two of the nine donor livers were obtained locally, and the other seven from cities 300 to 2,000 miles away. The hepatic grafts were preserved with Collin's solution I and transplanted by previously described techniques2.l after one to 101h hours of cold ischemia. Antibiotics were given prophylactically and for a few days postoperatively. Subsequent antibiotic therapy was given for specific indications only. Kidney transplantation. The kidneys were preserved with asanguinous perfusion or with Collin's solution and transplanted by conventional techniques 4 approximately one day after their removal. Liver recipients. CyA was started four to six hours before operation with a single oral dose of 17.5 mg/kg. Afterward the same daily dose was continued intramuscularly or orally as soon as diet was resumed ( Figs. 1 and 2) but with half the total amount in the morning and the other half in the evening. The daily dose was reduced if nephrotoxicity or other side effects were suspected (Fig. 2) . All surviving patients are still receiving CyA.
StaTZI et aJ.
Intravenous prednisone or hydrocortisone therapy was begun intraoperatively and converted afterward to the oral route as soon as possible. Postoperatively, patients who were in reasonable physiologic condition were given a five-da.y burst of prednisone (Figs. 1 and 2) beginning at 60 to 100 mg/day (depending on weight) and ending with maintenance doses of 5 to 20 mg/day. The steroid burst was omitted in those liver recipients who were gravely ill at the time of operation; they were given 10 to 20 mg/day. Further steroid weaning was variable. If rejections supervened, these were treated with boluses of hydrocortisone, 0.3 to 1.0 gm intravenously.
Kidney recipients. Immunosuppressive therapy (Figs. 3 and 4) was similar to that after liver transplantation except that steroids were used more liberally at the outset.5.6.8.9 In two of the kidney recipients, a second five-day burst of high dose steroid therapy was given (Fig. 3) .
RESULTS
Urer transplantation. Survival. One of the eight liver recipients died after 19
days. The homograft hepatic artery had thrombosed. The Renal transplantation in a l3-year-old girl who had previously rejected two grafts. Subsequently she developed widely reactive T warm antibodies (to 99% of the popUlation) making her a noncandidate for transplant. Eventually a kidney was obtained from a donor against whose lymphocytes the current recipient serum did not react, although stored serum still gave a positive crossmatch. The transplanted kidney survived the immediate immunologic insult and began to function within two weeks. She has had a good result.
death was ascribed to surgical error although no obvious technical mistake could be found at the anastomosis. The other patients have lived for 6 to 16th months. All are at home.
Liver function. All but one of the surviving patients has a serum bilirubin concentration less than 1.0 mg/ dl ( Table  I) . The exceptional patient developed jaundice one year postoperatively with a peak bilirubin concentration of 58 mg/dl. Eventually, a retained stent in the reconstructed common duct was removed at reoperation. In the succeeding four months, the bilirubin concentration has slowly fallen to its present level of 6 mg/dl. Other liver function tests of the survivors have been normal or near normal except for persistent low-grade elevations of serum transaminases or alkaline phosphatase in the exceptional patient described above.
Retransplantation. One of the seven surviving patients (No.6, Table I ) developed a huge abscess of the right hepatic lobe which contained a variety of bacteria as well as Candida albicans. After two weeks the damaged liver was replaced with a fresh homograft. The boy had a stormy postoperative course, but recovered completely.
Biliary tract reconstruction.
Five of the nine livers in the eight patients had bile duct reconstruction with ductto-duct anastomosis (Table I ). In one case, an anastomotic disruption necessitated reoperation and conversion to cho-ledochojejunostomy with a Roux-en-Y jejunal limb. Late secondary operation for stent removal was necessary in another recipient. Biliary reconstruction of two livers was satisfactory by primary Roux-en-Y choledochojejunostomy. The two final livers were reconstructed by anastomosing the graft gallbladder to a Roux limb (cholecystojejunostomy). One required conversion to choledochojejunostomy. The other liver was removed at retransplantation (Patient 6). Defective biliary drainage may have contributed to the destruction of this liver (see previous section).
Other major complications. Early deterioration of renal function occurred in two patients. both of whom had received nephrotoxic antibiotics as well as CyA. The most severe example is shown in Fig. 2 . The complication was treated by a reduction of CyA dosage. and in one instance (Fig. 2) by omitting the dose of CyA for several days and substituting azathioprine; dialysis was not required. One patient (No.5) had severe pulmonary edema and paralysis of the right phrenic nerve. requiring ventilatory support for three weeks. Patient 6 had recurrent laryngeal nerve paralysis.
Maintenance drug therapy (Table I ). The ability to use low maintenance doses of prednisone was noteworthy. In past experience with conventional immunosuppression. the single most important determinant of the quality of life following liver transplantation has been the requirements for steroid therapy.l.IO Hospitalization. The days in hospital after transplantation of the seven survivors averaged 56 ± 34 (SO) and ranged from 18 to 93. With conventional immunosuppressive therapy, patients with what were then considered to be favorable courses spent an average of nearly five months of the first postoperative year in the hospital. and those with protracted survival despite troubled courses spent more than six months of the first postoperative year in the hospitaJ. 1O Renal transplantation. The two patients whose recently stored sera had positive T warm crossmatches with their •• donors had a short-lived postoperative diuresis followed by oliguria for two and three one-half weeks, respectively, requiring temporary dialysis support (Fig. 4) . They recovered completely.
The third patient had a severe but quickly reversible rejection after six days (Fig. 3) . Hospitalization was required for 23, 38, and 24 days. The serum creatinine concentration in all three patients is below 2.0 mgjdl (Table II) . Follow-up has been 4 to 6\.7 months.
DISCUSSION
When renal transplantation was made feasible by the combined use of azathioprine and prednisone. 4 there were expressions of concern about subjecting pediatric recipients to such drastic therapy. II However. the first report of consistent success in treating infants and children 4 • 12 was promptly confirmed,ll·16 although acceptable results were obtained only with consanguineous donors. A number of special pediatric transplantation centers were established. l7 • 20 at which there usually has been a major effort to find genetically related donors. Failure to do so and consequent transplantation of cadaveric kidneys has been associated with a higher incidence of graft loss, death. and unacceptable morbidity from chronic high-dose steroid therapy. With organs such as the liver, there has been no option to the use of cadaveric donors. Major progress in cadaveric transplantation has been stalled for almost two decades despite efforts at tissue typing, better understanding of rejection. and modest improvements in immunosuppression made possible by adding antilymphoid globulins 2 . 16.21 or thoracic duct drainage to the original azathioprine-prednisone therapy.
Thus the description by Borel et ap2.2J of a fungus extract, cyclosporin A. which was a powerful immunosuppressant. and news of its first encouraging trials by Caine et aP4.25 were major and long awaited events. The drug became available for clinical testing in the United States in late 1979. Our consequent experience with CyA, for kidney and liver transplantation. and our recommendations about its use with conservative doses of steroids have been reported and are based principally upon observations in adults. 5·9
In spite of the superior results obtained when CyA is used alone 2 4-27 or in combination with low-dose steroids. 5 . 9 the agent has not been available for evaluation in patients under 18 years of age because of the unknown risks from side effects. The initial fear that there might be an exorbitant incidence of de novo lymphomas 25 has proved unfounded.7.8 Nephrotoxicity, hepatotoxicity, hirsutism. motor dyskinesias. and gum hyperplasia have been manageable by dose adjustments. 7 . 26 Cyclosporin A was released on a compassionate basis to our pediatric liver recipients after it had become apparent that the chance of survival in adults after hepatic replacement was nearly doubled with use of the drug.' The same benefit has been seen in the children receiving livers. of whom seven of eight are alive after six to 16\.7 months. The pediatric recipients were by no means free of the complications that have plagued efforts at liver transplantation in the past, but with the good control of rejection achieved with low-dose steroid therapy, these complications (including retransplantation in the face of an otherwise lethal infection in the first graft) could be managed.
Cyclosporin A was released compassionately to the three kidney recipients for equally forceful reasons. These patients were having problems with dialysis. Under the best of circumstances, retransplantation has a lowered graft survival, and a one-year mortality that has been as high as 40%. 28 In addition, with the presence of widely reacting T warm antibodies in their sera, our patients had even pllOl'er prospects of successful cadaveric renal retransplantation; in most centers, they would have been considered noncandidates for such an heroic effort. Two of the three patients had been waiting for more than three years for a cadaveric kidney. Although severe immunologic reactions ensued postoperatively, necessitating brief continuation of dialysis for two of the three recipients, all three have had a good result and have not required excessive steroid therapy.
Caution is justifiable in restricting the use of new techniques and drugs to adults during their developmental phase. However. pediatric recipients whose growth and development patterns are severely inhibited by conventional immunosuppression with high doses of steroids should benefit most from CyA therapy when it is released for more general use. In our liver and kidney recipients. the plan is to reduce the maintenance prednisone doses even lower than the present level.
Randomized controlled trials comparing cyclosporin A and steroid therapy with conventional immunosuppression for renal transplantation in adults are underway in a number of centers. including our own. The results of these trials should be applicable in making decisions about treatment 'P'I'otocols for infants and children.
